drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
Anti–TNF-α chimeric IgG1 monoclonal antibody that neutralizes soluble and transmembrane TNF-α, blocking TNFR→NF-κB signaling, reducing inflammatory cytokines/adhesion molecules, and inducing apoptosis of activated T cells/macrophages to dampen Th1/Th17-driven gut inflammation.
nci_thesaurus_concept_id
C1789
nci_thesaurus_preferred_term
Infliximab
nci_thesaurus_definition
A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)
drug_mesh_term
Infliximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody against TNF-α that neutralizes soluble and transmembrane TNF-α, blocking TNFR→NF-κB signaling, decreasing proinflammatory cytokines and adhesion molecules, and inducing apoptosis of activated T cells and macrophages to suppress Th1/Th17-driven inflammation.
drug_name
Infliximab
nct_id_drug_ref
NCT05813860